CIStem Molecular Corp. Names Jack W. Reich, Ph.D., Chairman of Its Board of Directors.Business Editors/Health & Medical Writers BIOWIRE2K SAN DIEGO--(BW HealthWire)--March 22, 2000 CIStem Molecular Corp., the first Systems Biology Systems biology, a field of study in the biosciences, focuses on the systematic study of complex interactions in biological systems. Particularly from 2000 onwards, the term is used widely in the biosciences, and in a variety of contexts. company, today announced that Jack W. Reich, Ph.D. has been named chairman of its board of directors. Reich brings over 25 years of business and scientific expertise to CIStem, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Anne Crossway, Ph.D., MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration , president and chief executive officer of CIStem. CIStem is focused on regulomics, the study of gene expression at the level of genetic network regulatory mechanisms, making the vital connection from genomics information to gene-based pharmaceutical and agricultural products. "We are extremely pleased that Dr. Reich has agreed to be chairman of our Board," said Crossway. "His business development and entrepreneurial experiences at Collateral Therapeutics, MyoTech, and Gensia will greatly assist us as we pursue strategic partnership agreements with biotechnology and pharmaceutical companies." Reich joins CIStem's six member board which also includes the following individuals: Crossway; Craig S. Andrews, JD, partner at Brobeck Phleger & Harrison LLP LLP - Lower Layer Protocol ; Stuart Kauffman Stuart Alan Kauffman (born September 28, 1939) is a theoretical biologist and complex systems researcher, who has given much thought to the origin of life on Earth. He is best known for arguing that the complexity of biological systems and organisms might result as much from , MD, co-founder of CIStem and chief scientific officer of Bios Group LP; Robert MacDonald Robert MacDonald may refer to:
http://upenn.edu/. Address: Philadelphia, PA, USA. University City Science Center. Reich is a co-founder of Collateral Therapeutics Inc. and has served as a director and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of the company since April 1995 and as chairman since June 1999. In May 1995, Reich co-founded MyoTech Inc., a newly established venture based upon a novel clinical service model and drug therapy to treat chronic muscle injury, which was sold in November 1996. Reich was also senior vice president of Enterprise Partners, a Southern California Southern California, also colloquially known as SoCal, is the southern portion of the U.S. state of California. Centered on the cities of Los Angeles and San Diego, Southern California is home to nearly 24 million people and is the nation's second most populated region, based venture capital firm that has played a key role in developing biotechnology and medical technology companies. From September 1987 to October 1994, Reich was vice president, regulatory affairs and quality operations of Gensia Inc. ("Gensia"), a biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the diagnosis and treatment of human disease. Reich received a B.A. in Biology from Washington and Jefferson College, a B.S. in Pharmacy from Creighton University, an M.S. in Hospital Pharmacy Administration from Temple University and a Ph.D. in Pharmaceuticals-International Pharmaceutical Administration from Temple University. CIStem, a Systems Biology company, has proprietary technologies for commercialization of the genetic regulatory networks controlling gene expression in all organisms -- the next step beyond genomics. CIStem owns high specificity molecular technologies for aggressively identifying key regulatory elements in mass. This molecular approach is a short cut that obviates the need for extensive gene expression analysis. Aided by proprietary algorithms, CIStem will identify genes that are critical mediators in medically important regulatory networks and, thus, the best drug discovery targets. CIStem is currently pursuing collaborations and partnerships with major pharmaceutical and biotechnology companies. |
|
|||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion